{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:57:37Z","timestamp":1793465857448,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Intensificaci\u00f3n FIS"},{"name":"FEDER Funds","award":["REDINREN RD016\/0019"],"award-info":[{"award-number":["REDINREN RD016\/0019"]}]},{"name":"Plan National Maladies Rares of the French Ministry of Health"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ymgme.2018.02.014","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T04:37:03Z","timestamp":1519792623000},"page":"416-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":596,"title":["Fabry disease revisited: Management and treatment recommendations for adult patients"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-9523","authenticated-orcid":false,"given":"Alberto","family":"Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-007X","authenticated-orcid":false,"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Desnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Politei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Burlina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hopkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Laney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3372-7850","authenticated-orcid":false,"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Waldek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.02.014_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0025","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.semperi.2015.03.005","article-title":"Newborn screening for lysosomal storage disorders","volume":"39","author":"Matern","year":"2015","journal-title":"Semin. Perinatol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0030","first-page":"54","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2015","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0040","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0045","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease","volume":"9","author":"Lukas","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0085","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0090","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0095","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cns.12542","article-title":"Pain in Fabry disease: practical recommendations for diagnosis and treatment","volume":"22","author":"Politei","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0100","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10897-013-9613-3","article-title":"Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors","volume":"22","author":"Laney","year":"2013","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0105","first-page":"51","article-title":"Recommendations on reintroduction of agalsidase beta for patients with Fabry disease in Europe, following a period of shortage","volume":"8","author":"Linthorst","year":"2013","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0110","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10545-010-9261-9","article-title":"Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group","volume":"34","author":"Gal","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2010.11.155","article-title":"European Medicines Agency. Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT)","volume":"102","author":"Linthorst","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ncpneph0806","article-title":"Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults","volume":"4","author":"Ortiz","year":"2008","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0130","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","article-title":"Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance","volume":"177","author":"Smid","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0135","first-page":"83","article-title":"Uncertain diagnosis of Fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up","volume":"17","author":"van der Tol","year":"2014","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0140","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ymgme.2014.08.007","article-title":"Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis","volume":"114","author":"van der Tol","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0145","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ymgme.2015.11.014","article-title":"Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort","volume":"117","author":"Arends","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0150","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The management and treatment of children with Fabry disease: a United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108641","article-title":"Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of Fabry knockout male mice","volume":"9","author":"Lakoma","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.02.014_bb0160","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"Germain","year":"2002","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0165","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0170","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: natural history data from the Fabry registry","volume":"25","author":"Ortiz","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0175","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0180","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1651-2227.2002.tb03113.x","article-title":"Arterial remodelling in Fabry disease","volume":"91","author":"Boutouyrie","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0185","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular involvement in Fabry disease: current status of knowledge","volume":"46","author":"Kolodny","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2018.02.014_bb0190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10545-013-9643-x","article-title":"Cognitive dysfunction and depression in Fabry disease: a systematic review","volume":"37","author":"Bolsover","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0195","doi-asserted-by":"crossref","DOI":"10.3402\/ecrj.v2.26721","article-title":"Fabry disease, respiratory symptoms, and airway limitation - a systematic review","volume":"2","author":"Svensson","year":"2015","journal-title":"Eur. Clin. Respir. J."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0200","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","article-title":"Fabry disease and the skin: data from FOS, the Fabry outcome survey","volume":"157","author":"Orteu","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0205","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1399-0004.2005.00457.x","article-title":"Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease","volume":"68","author":"Germain","year":"2005","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0210","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.ejhg.5201798","article-title":"Three-dimensional face shape in Fabry disease","volume":"15","author":"Cox-Brinkman","year":"2007","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0215","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0220","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2215\/CJN.01820217","article-title":"Long-term dose-dependent agalsidase effects on kidney histology in Fabry disease","volume":"12","author":"Skrunes","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fcvm.2016.00007","article-title":"Electrocardiographic changes and arrhythmia in Fabry disease","volume":"3","author":"Namdar","year":"2016","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0230","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0235","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry","volume":"57","author":"Patel","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0240","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2018.02.014_bb0245","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0250","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.amjcard.2017.04.016","article-title":"Arrhythmia and clinical cardiac findings in children with Anderson-Fabry disease","volume":"120","author":"Wilson","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.389","article-title":"Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female Fabry patients: a multicenter Fabry Registry study","author":"Germain","year":"2018","journal-title":"Mol. Genet. Genomic. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0260","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/heartjnl-2014-306782","article-title":"Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry disease","volume":"101","author":"Patel","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2018.02.014_bb0265","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0270","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry Outcome Survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0275","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0280","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.ymgme.2014.12.067","article-title":"Fabry disease: the \u03b1-galactosidase A (GLA) c.427G>A (A143T) mutation, effect of the 5\u2032-10C>T polymorphism","volume":"114","author":"Desnick","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0285","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0290","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","article-title":"The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies","volume":"114","author":"Ferreira","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0295","first-page":"99","article-title":"Lyso-Gb3 indicates that the alpha-galactosidase A mutation D313Y is not clinically relevant for Fabry disease","volume":"7","author":"Niemann","year":"2013","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol","year":"2014","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0305","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0310","article-title":"Biomarkers for diagnosing and staging of Fabry disease","author":"Kr\u00e4mer","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0315","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1076\/opge.24.3.129.15609","article-title":"Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients","volume":"24","author":"Orssaud","year":"2003","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0320","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0325","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2018.02.014_bb0330","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0335","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0340","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0345","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0350","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0355","first-page":"21","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry outcome survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0360","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0365","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0370","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment","volume":"10","author":"Kampmann","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0375","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0380","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0385","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2018.02.014_bb0390","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0395","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"Deegan","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0400","first-page":"95","article-title":"Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for Fabry disease","volume":"25","author":"Goker-Alpan","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0405","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128351","article-title":"Rapid immunochromatographic detection of serum anti-alpha-galactosidase a antibodies in Fabry patients after enzyme replacement therapy","volume":"10","author":"Nakano","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.02.014_bb0415","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0420","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0425","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0430","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","article-title":"Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme","volume":"10","author":"Bodensteiner","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0435","first-page":"1","article-title":"Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"76","author":"KDIGO","year":"2009","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0440","first-page":"337","article-title":"2012 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"2","author":"KDIGO","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0445","author":"KDIGO"},{"key":"10.1016\/j.ymgme.2018.02.014_bb0450","first-page":"1","article-title":"2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"KDIGO","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0455","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0460","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0465","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0470","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","article-title":"Quality of life in patients with Fabry disease: a systematic review of the literature","volume":"10","author":"Arends","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0475","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0480","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2016.04.033","article-title":"Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy","volume":"118","author":"Weidemann","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0485","first-page":"807","article-title":"Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients","volume":"32","author":"Skrunes","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0490","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0495","first-page":"57","article-title":"A retrospective survey studying the impact of Fabry disease on pregnancy","volume":"21","author":"Holmes","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0500","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10897-007-9128-x","article-title":"Diagnosis of Fabry disease via analysis of family history","volume":"17","author":"Laney","year":"2008","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0505","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","article-title":"Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals","volume":"13","author":"Wang","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0510","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","article-title":"Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri","volume":"166","author":"Hopkins","year":"2015","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0515","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","article-title":"Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2018.02.014_bb0520","article-title":"Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy","author":"Burlina","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0525","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2119\/molmed.2012.00002","article-title":"Fabry disease: incidence of the common later-onset alpha-galactosidase A IVS4+919G\u2014>A mutation in Taiwanese newborns\u2013superiority of DNA-based to enzyme-based newborn screening for common mutations","volume":"18","author":"Chien","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0530","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ymgme.2013.03.008","article-title":"Fabry patients' experiences with the timing of diagnosis relevant for the discussion on newborn screening","volume":"109","author":"Bouwman","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0535","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ymgme.2016.07.009","article-title":"Patients' perspectives on newborn screening for later-onset lysosomal storage diseases","volume":"119","author":"Lisi","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.014_bb0540","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10897-017-0139-y","article-title":"The psychosocial impact of carrying a debated variant in the GLA gene","volume":"27","author":"Macklin","year":"2018","journal-title":"J. Genet. Couns."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217307680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217307680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:21:47Z","timestamp":1761088907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719217307680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1096719217307680"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.014","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry disease revisited: Management and treatment recommendations for adult patients","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}